Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.60 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30358375 | 0.83 | CYP19A1 (0.71) | CYP19A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL1733117 | 0.83 | CYP19A1 (0.71) | CYP19A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| Dihydrochalcone SCHEMBL29359372 | 0.82 | CYP19A1 (0.80) | CYP19A1KDM4EALDH1A1HPGDNAPRT | |
| Dihydrochalcone SCHEMBL2827303 | 0.82 | CYP19A1 (0.80) | CYP19A1KDM4EALDH1A1HPGDNAPRT | |
| Hydrochloric Acid SCHEMBL3785617 | 0.81 | CYP19A1 (0.69) | CYP19A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| Dihydrochalcone SCHEMBL7540273 | 0.80 | CYP19A1 (0.77) | CYP19A1KDM4EALDH1A1HPGDNAPRT | |
| SCHEMBL9475090 | 0.80 | PLOD2 (0.60) | TBXAS1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL16310778 | 0.79 | TBXAS1 (0.58) | CYP19A1TBXAS1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL27939457 | 0.77 | TBXAS1 (0.64) | TBXAS1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4951237 | 0.77 | CYP19A1 (0.61) | CYP19A1KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8715761-B2 | Flavor molecules | GIVAUDAN S.A. (CH) | 2014-05-06 | — | — | US | disclosed |
| US-8715761-B2 | Flavor molecules | GIVAUDAN S.A. (CH) | 2014-05-06 | — | — | US | disclosed |
| US-8715761-B2 | Flavor molecules | GIVAUDAN S.A. (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-8449936-B2 | Flavor molecules | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| US-8449936-B2 | Flavor molecules | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| US-8449936-B2 | Flavor molecules | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| WO-2012054528-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| EP-2259689-B1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2011-11-16 | — | — | EP | disclosed |
| US-20100272656-A1 | Flavor Molecules | GIVAUDAN SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100272656-A1 | Flavor Molecules | GIVAUDAN SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100272656-A1 | Flavor Molecules | GIVAUDAN SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100040753-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100040753-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100040753-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2010-02-18 | — | — | US | disclosed |
| WO-2009105906-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272656-A1 | Flavor Molecules | TAS2R30, TAS2R31, TAS2R1 | CYP19A1 3585/4885TBXAS1 2799/4885CYP1A2 2674/4885 |
| US-20100040753-A1 | FLAVOR MOLECULES | TAS2R30, TAS2R31, TAS2R1 | CYP19A1 3585/4885TBXAS1 2799/4885CYP1A2 2674/4885 |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | CYP19A1 2441/4885TBXAS1 2837/4885CYP1A2 4702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.